|2.||Wilms Tumor (Wilm's Tumor)
|4.||Neoplasm Metastasis (Metastasis)
|1.||Sugiyama, Haruo: 59 articles (10/2015 - 05/2002)|
|2.||Oji, Yusuke: 37 articles (07/2015 - 06/2003)|
|3.||Oka, Yoshihiro: 36 articles (07/2015 - 06/2003)|
|4.||Tsuboi, Akihiro: 32 articles (07/2015 - 07/2003)|
|5.||Graf, Norbert: 27 articles (08/2015 - 09/2003)|
|6.||Green, Daniel M: 24 articles (07/2015 - 05/2002)|
|7.||Hosen, Naoki: 23 articles (07/2015 - 07/2003)|
|8.||Nishida, Sumiyuki: 23 articles (07/2015 - 11/2003)|
|9.||Nakajima, Hiroko: 20 articles (07/2015 - 07/2003)|
|10.||Dome, Jeffrey S: 19 articles (10/2014 - 03/2002)|
|1.||Dactinomycin (Ac-De)FDA LinkGeneric
03/21/1966 - "Role of dactinomycin in the improved survival of children with Wilms' tumor."
09/19/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D."
07/25/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D."
09/01/2008 - "This phase 2 pediatric trial evaluated the efficacy and further defined the toxicity profile of recombinant TNF (rTNF) and dactinomycin in patients with recurrent or refractory Wilms tumor. "
12/01/2002 - "Clinical studies of actinomycin D with special reference to Wilms' tumor in children. "
|2.||Vincristine (Oncovin)FDA LinkGeneric
10/01/2004 - "Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor."
10/01/2004 - "We report a 10-year-old female with Wilms tumor (WT) who developed severe neuropathy after the fifth weekly dose of vincristine. "
01/01/1970 - "[Action of vincristine in nephroblastomas]."
01/01/1970 - "Vincristine sulfate and radiation therapy in metastatic Wilms' tumor."
06/01/1968 - "Vincristine (NSC-67574) therapy for Wilms' tumor."
|3.||Etoposide (VP 16)FDA LinkGeneric
08/01/2014 - "Finally, by integrating clinical follow-up information with methylation levels we propose etoposide-induced 2.4 and Wilms tumor 1 as novel prognostic markers related to recurrence-free survival. "
09/01/1999 - "[A case of metastatic nephroblastoma in an adult with favorable outcome under cisplatyl, etoposide]."
08/01/1993 - "Thirty-one patients with relapsed or refractory Wilms' tumor from three British and 14 French centers were treated with intravenous (IV) etoposide 200 mg/m2 daily for 5 days. "
08/01/1993 - "It is concluded that etoposide in this schedule is an active agent in Wilms' tumor and should be considered for inclusion in regimens for high-risk patients, such as those with metastatic disease at diagnosis and those who relapse after multiagent chemotherapy."
08/01/1993 - "Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group."
|4.||Carboplatin (JM8)FDA LinkGeneric
01/01/1994 - "Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group."
09/01/2014 - "Treatment of Wilms tumor using carboplatin compared to therapy without carboplatin."
07/01/1995 - "This data indicate that carboplatin seems to be an additional effective drug in patients with previously untreated Wilms' tumor of favorable histology."
07/01/1995 - "The overall response rate after a preoperative single-dose of 600 mg/m2 carboplatin in untreated patients with stage IV Wilms' tumor is encouraging and the toxicity acceptable. "
07/01/1995 - "A total of nine children with previously untreated stage IV Wilms' tumor of favorable histology were treated according to the Austrian/Hungarian Wilms' Tumor Protocol 89 and received a preoperative single dose of carboplatin as an "up front" window therapy. "
09/01/2015 - "In this study, we comprehensively studied how TCR chain centricity affects reactivity to target self-MHC/peptide complexes and alloreactivity using the TCR, clone TAK1, which is specific for human leukocyte antigen-A*24:02/Wilms tumor 1(235-243) (A24/WT1(235)) and cross-reactive with B*57:01 (B57). "
05/01/1990 - "Moreover, this study shows that tumoral cells in nephroblastoma share several antigens with cells from lymphoid lineage (CD24, CALLA, and CD26) as do developing and mature kidney cells. "
05/01/2012 - "After lentiviral transfer of a TCR specific for the Wilms tumor 1 (WT1) antigen, these TCR-edited cells expressed the new TCR at high levels, were easily expanded to near purity and were superior at specific antigen recognition compared to donor-matched, unedited TCR-transferred cells. "
11/01/2009 - "We studied renal biopsies with FSGS, not otherwise specified (NOS), tip lesion, or collapsing variants (COLL), versus secondary FSGS or cases without segmental sclerotic lesions where a diagnosis of MCD versus FSGS could not be established (undefined [UNDEF]) and compared the expression of DG, FSP1, and podocyte Wilms' tumor antigen (WT1). "
07/16/2009 - "CD4(+)CD25(bright)Foxp3(+) Tregs also suppress the generation of cytotoxic T lymphocytes specific for the Wilms tumor antigen 1, resulting in more than an 80% decrease in specific target cell lysis. "
|6.||Messenger RNA (mRNA)IBA
01/01/2013 - "Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo."
01/01/2014 - "In this study, we first evaluate the expression of S100A4 mRNA in Wilms tumor (WT) and its relationship to the clinicopathological parameters and prognosis. "
04/01/2009 - "This study developed a novel MRD monitoring method targeting Wilms' tumor gene (WT1) mRNA using reverse transcription loop-mediated isothermal amplification (RT-LAMP). "
01/01/2015 - "The mRNA levels and protein expression of synaptopodin and Wilms' tumor 1 (WT1) were determined by real-time PCR, Western blotting and/or immunofluorescence, respectively. "
01/01/2014 - "S100A4 mRNA as a prognostic marker and therapeutic target in Wilms tumor (WT)."
01/01/1989 - "The purpose of this study was to evaluate the antitumor activity and tolerability of ifosfamide (IFO) at a dose of 3 g/m2, given on 2 consecutive days every 2 weeks, in advanced Wilms' tumor patients in whom conventional therapy had failed. "
01/01/1989 - "A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor."
05/01/1988 - "Twenty-one patients with advanced Wilms' tumor entered a phase II study with high-dose ifosfamide (3 g/m2 over two days every 15 days). "
05/01/1988 - "Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology."
01/01/2003 - "Ifosfamide has definite activity in nephroblastoma, where it represents the treatment of choice for children who are not cured by front-line chemotherapy, and for the adults who are diagnosed with this uncommon disease. "
12/01/2005 - "Our studies show that the gut is initially devoid of a mesothelium but that serosal mesothelial cells expressing the Wilm's tumor protein (Wt1) move to and over the gut. "
11/01/1996 - "Study of genotype/phenotype relationships involving the Wilms' tumor (WT) gene, WT1, in WT patients has provided insights into the function of the WT1 protein, a transcriptional regulator, and has suggested possible mutational mechanisms important in the etiology of WT. For example, the identification of deletion/insertion mutations in the first exon implicates a deletion hotspot consensus sequence in the etiology of these mutations. "
05/01/2015 - "Wilms' tumor 1 (WT1) protein expression in human developing tissues."
05/01/2015 - "Oncofetal expression of Wilms' tumor 1 (WT1) protein in human fetal, adult and neoplastic skeletal muscle tissues."
08/29/2014 - "We report here that the Wilms tumor protein, WT1, which is necessary for normal kidney development, activates transcription of the AOC1 gene. "
|9.||Doxorubicin (Adriamycin)FDA LinkGeneric
05/01/2010 - "Medical records were reviewed to identify cases of PHTN identified with late liver/spleen/gastric toxicities in a cohort of 5,195 patients treated with National Wilms' Tumor Studies (NWTS) protocols 1 to 4. A nested case control study (5 controls/case) was conducted to determine relationships among doxorubicin, radiation therapy (RT) dose to the liver, patient gender, and PHTN. "
09/01/2004 - "Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies."
01/01/1982 - "It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation."
04/01/2012 - "Preoperative chemotherapy with doxorubicin in Wilms tumor."
01/01/1995 - "Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin."
|10.||DNA (Deoxyribonucleic Acid)IBA
12/01/2009 - "New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual study."
02/01/2013 - "We confirmed hypomethylation of both satellite α (Sat α) and satellite 2 (Sat 2) DNA in Wilms tumor samples compared with normal kidney. "
06/01/2010 - "Therefore 8 SNPs-distributed over the whole length of the WTX gene-were investigated by high resolution melting curve analysis (HRMA) and sequencing of genomic DNA from nephroblastoma patients (NB) and controls. "
07/01/2009 - "To construct the eukaryotic expression vector harboring Wilms' tumor gene (WT1y) and assess the cytotoxic T lymphocyte (CTL) response specific to the DNA vaccine of WT1y product in Balb/c mice and in vitro cultured cells. "
07/01/2009 - "[Human cytotoxic T lymphocyte responses specific to the DNA vaccine of Wilms' tumor gene product]."
|1.||Drug Therapy (Chemotherapy)
08/01/2010 - "We report a late recurrent relapse of Wilms tumor successfully treated with high-dose chemotherapy and autologous stem cell rescue in his third complete response who remains disease free 15 months posttransplant."
12/01/1993 - "[Rapid efficacy of preoperative chemotherapy in nephroblastoma involving cardiac cavities]."
07/01/1990 - "A chemotherapy regimen known to be successful in childhood Wilms tumor was shown to be equally effective in our adult patient."
03/15/1984 - "The second MRC nephroblastoma trial was devised to determine whether more intensive chemotherapy in the early stages and multiple chemotherapy in the poorer prognosis groups would give improved results. "
06/15/2005 - "The results suggest that Wilms' tumor clones with +1q are not obliterated by preoperative chemotherapy, whereas cytogenetically more complex clones with +7q and/or imbalances at 7p seem more responsive and are more likely to be eliminated by chemotherapeutic treatment."
01/01/1992 - "Lastly, bilateral partial nephrectomy is the best treatment for bilateral nephroblastoma."
07/15/1990 - "Patients with Stage I (Cassady) Wilms' tumor can be successfully treated with nephrectomy alone, thereby eliminating the toxicity of adjuvant therapy."
10/01/2012 - "With the increasing use of nephron sparing surgery in Wilms tumor, we reviewed pathological features from Wilms tumor radical nephrectomy specimens to determine the potential efficacy of a nephron sparing approach. "
02/01/2015 - "In this study, we compare the outcomes of the retroperitoneal and transabdominal approaches in doing partial nephrectomy for bilateral Wilms tumor. "
11/01/2014 - "We present the largest series so far of minimally invasive nephrectomies for nephroblastoma based on a multinational trial. "
01/01/2008 - "In the United States, the National Wilms Tumor Study (NWTS) advises surgery prior to chemo- and radiotherapy. "
03/01/1999 - "The purpose of this study was to use sonography to evaluate the size of the ovaries and uterus in survivors of Wilms' tumor who underwent radiotherapy. "
01/01/1994 - "Radiotherapy in the SIOP (International Society of Pediatric Oncology) nephroblastoma studies: a review."
07/01/1990 - "The modern approach to Wilms' tumor and its treatment based on the combination of surgery with chemo- and radiotherapy raised the survival rate to 80-95%, as shown by several cooperative studies performed in the United States and Europe. "
11/01/1988 - "Twenty-three of 303 patients (7.6%) entered into National Wilms' Tumor Study Number 2 (NWTS-2) with groups II, III, and IV disease experienced 26 toxic events thought to be related to radiotherapy (RT). "
06/01/2014 - "Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies."
06/01/2010 - "Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy. "
11/01/2009 - "Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy."
11/01/2009 - "One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial. "
01/01/2014 - "Wilms' tumor 1 (WT1) is expressed in most glioblastoma samples, and immunotherapy targeting WT1 has proven to be effective in recurrent glioblastoma. "
|5.||Combination Drug Therapy (Combination Chemotherapy)
02/01/1993 - "Pathologic review revealed features of true extrarenal Wilms' tumor, and the patient remains in complete remission following surgery and combination chemotherapy. "
04/01/1982 - "[Improved prognosis in Wilms' tumor due to adjuvant combination drug therapy]."
01/01/1985 - "The results of preoperative polychemotherapy of nephroblastoma in 14 children are presented. "
01/01/1985 - "[Evaluation of the effectiveness of preoperative polychemotherapy of nephroblastomas in children by angiography, ultrasonic tomography and computed tomography]."
01/01/1984 - "Evaluation of combination chemotherapy in Wistar/Furth rats bearing transplantable Wilms' tumor."